About us
We are EXACT Therapeutics AS (“EXACT-Tx”), a clinical-stage biopharmaceutical company developing a novel ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®).
ACT® is a unique approach to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of applications, including oncology (chemotherapy and immunotherapy), neurological conditions, and gene therapy.
EXACT Therapeutics and our ACT® platform builds on decades of R&D efforts within ultrasound and microbubbles performed by the former world leading diagnostic company; Nycomed Imaging AS (now GE Healthcare).
In 2012, three core scientists spun out from GE Healthcare to form EXACT Therapeutics – with the aim to develop ACT® for therapeutic applications.
In 2013 EXACT Therapeutics was awarded a €1.8M grant from the Research Council of Norway (RCN) and entered a 4-year explorative development program together with strong academic partners at Institute of Cancer Research / Royal Marsden Hospital (UK) and The Norwegian University of Science and Technology (NTNU) to further optimise the ACT® formulation and conduct an extensive preclinical program focused in oncology. This development program achieved pre-clinical Proof of Concept when combining ACT® with a wide range of chemotherapeutic agents for treatment of a number of oncology indications.
Late 2016 EXACT Therapeutics completed a Series A financing round, subscribed by a number of Norwegian healthcare angel investors.
Early 2017 EXACT Therapeutics was awarded another substantial (€2.8M ) grant from RCN, followed by a Series B financing round to fund a full development program intended to take ACT® into early clinical trials.
In 2020 EXACT Therapeutics was listed in the Oslo Stock Exchange Euronext Growth Market under the ticker EXTX-ME.